A Phase 3, Multicenter, Open-Label, Long-Term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Project: Other project

Project Details

StatusActive
Effective start/end date10/25/21 → 10/24/26

Funding

  • Mitsubishi Tanabe Pharma: $67,947.38